Abstract
We have screened for mutations in exons 5–8 of the p53 gene in a series consisting of 189 patients with urinary bladder neoplasms. 82 (44%) neoplasms were lowly malignant (Ta, G1–G2a) and 106 (56%) were highly malignant (G2b–G4 or ≥T1). Only one mutation was in a lowly malignant urinary bladder neoplasm, in total we found p53 mutations in 26 (14%) of the 189 patients. 30% of the samples had loss of heterozygosity (LOH) for one or both of the p53 exogenic (CA)n repeat and the p53 intragenic (AAAAT)n repeat markers. 31 samples (21%) showed LOH but were not mutated, suggesting other mechanisms inactivating p53 than mutations. 4 mutations were found at codon 280 and 2 mutations were found at codon 285, 2 previously reported hot spots for urinary bladder cancer. The study indicate a boundary between G2a and G2b tumours concerning the occurrence of genetic events affecting p53 function; moderately differentiated (G2) urinary bladder neoplasms probably are genetically heterogeneous which supports the suggestion that they should not be grouped together but instead, for example, be categorized as either lowly or highly malignant. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG and Harris CC (1999) Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol 187: 8–18
Berggren P, Hemminki K and Steineck G (2000a) p53 intron 7 polymorphisms in urinary bladder cancer patients and controls. Mutagenesis 15: 57–60
Berggren P, Steineck G and Hemminki K (2000b) A rapid fluorescence based multiplex polymerase chain reaction – single-strand conformation polymorphism method for p53 mutation detection. Electrophoresis 21: 2335–2342
Bergkvist A, Ljungqvist A and Moberger G (1965) Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years. Acta Chir Scand 130: 371–378
Bringuier PP, McCredie M, Sauter G, Bilous M, Stewart J, Mihatsch MJ, Kleihues P and Ohgaki H (1998) Carcinomas of the renal pelvis associated with smoking and phenacetin abuse: p53 mutations and polymorphism of carcinogen-metabolising enzymes. Int J Cancer 79: 531–536
Carbin BE, Ekman P, Gustafson H, Christensen NJ, Sandstedt B and Silfversward C (1991) Grading of human urothelial carcinoma based on nuclear atypia and mitotic frequency. I. Histological description. J Urol 145: 968–971
Carbone D, Chiba I and Mitsudomi T (1991) Polymorphism at codon 213 within the p53 gene. Oncogene 6: 1691–1692
Centre for epidemiology (1998) Cancer incidence in Swede 1996 The national board of health and welfare: Stockholm
Cohen SM, Samuel MC, Tomoyuki S and Steinech G (2000) Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol 205: 105–115
Coles C, Thompson AM, Elder PA, Cohen BB, Mackenzie IM, Cranston G, Chetty U, Mackay J, Macdonald M, Nakamura Y, Hoyhtim B and Steel CM (1990) Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis. Lancet 336: 761–763
Epstein JI, Amin MB, Reuter VR and Mostofi FK (1998) The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22: 1435–1448
Esposti PL and Zajicek J (1972) Grading of transitional cell neoplasms of the urinary bladder from smears of bladder washings. A critical review of 326 tumors. Acta Cytol 16: 529–537
Feinstein E, Cimino G, Gale RP, Alimena G, Berthier R, Kishi K, Goldman J, Zaccaria A, Berrebi A and Canaani E (1991) p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci USA 88: 6293–6297
Fields S and Jang SK (1990) Presence of a potent transcription activating sequence in the p53 protein. Science 249: 1046–1049
Fujimoto K, Yamada Y, Okajima E, Kakizoe T, Sasaki H, Sugimura T and Terada M (1992) Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 52: 1393–1398
Futreal PA, Barrett JC and Wiseman RW (1991) An Alu polymorphism intragenic to the TP53 gene. Nucleic Acids Res 19: 6977
Greenblatt MS, Bennett WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855–4878
Hainaut P and Hollstein M (2000) p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77: 81–137
Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M, Harris CC and Montesano R (1998) IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res 26: 205–213
Hall RR and Prout GR (1990) Staging of bladder cancer: is the tumor, node, metastasis system adequate?. Semin Oncol 17: 517–523
Hollstein M, Moeckel G, Hergenhahn M, Spiegelhalder B, Keil M, Werle-Schneider G, Bartsch H and Brickmann J (1998) On the origins of tumor mutations in cancer genes: insights from the p53 gene. Mutat Res 405: 145–154
IARC (1985) IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Vol. 38. pp. 244–270
Isobe M, Emanuel BS, Givol D, Oren M and Croce CM (1986) Localization of gene for human p53 tumour antigen to band 17p13. Nature 320: 84–85
Jones MH and Nakamura Y (1992) Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chromosomes Cancer 5: 89–90
Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C and Vogelstein B (1991) Identification of p53 as a sequence-specific DNA-binding protein. Science 252: 1708–1711
Kleihues P, Schauble B, zur Hausen A, Esteve J and Ohgaki H (1997) Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 150: 1–13
Knowles MA (1999a) The genetics of transitional cell carcinoma: progress and potential clinical application. BJU Int 84: 412–427
Knowles MA (1999b) Identification of novel bladder tumour suppressor genes. Electrophoresis 20: 269–279
Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820–823
Lane DP and Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278: 261–263
Lianes P, Orlow I, Zhang ZF, Oliva MR, Sarkis AS, Reuter VE and Cordon-Cardo C (1994) Altered patterns of MDM2 and TP53 expression in human bladder cancer [see comments]. J Natl Cancer Inst 86: 1325–1330
Lindahl T (1979) DNA glycosylases, endonucleases for apurinic/apyrimidinic sites, and base excision-repair. Prog Nucleic Acid Res Mol Biol 22: 135–192
Lohmann D, Putz B, Reich U, Bohm J, Prauer H and Hofler H (1993) Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data. Am J Pathol 142: 907–915
Malmstrom PU (1988) Prognosis of transitional cell bladder carcinoma. With special reference to ABH blood group isoantigen expression and DNA analysis. Scand J Urol Nephrol Suppl 112: 1–55
Malmstrom PU, Busch C and Norlen BJ (1987) Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand J Urol Nephrol 21: 185–195
Miyamoto H, Kubota Y, Shuin T, Torigoe S, Hosaka M, Iwasaki Y, Danenberg K and Danenberg PV (1993) Analyses of p53 gene mutations in primary human bladder cancer. Oncol Res 5: 245–249
Nakai H, Misawa S, Toguchida J, Yandell DW and Ishizaki K (1992) Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. Cancer Res 52: 6588–6593
Prosser J and Condie A (1991) Biallelic ApaI polymorphism of the human p53 gene (TP53). Nucleic Acids Res 19: 4799
Raycroft L, Wu HY and Lozano G (1990) Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249: 1049–1051
Sambrook J, Fritschookstein EF and Maniatis T (1989) Molecular cloning. A laboratory manual. Cold Spring Harbour Press.
Schultz DC, Vanderveer L, Berman DB, Hamilton TC, Wong AJ and Godwin AK (1996) Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res 56: 1997–2002
Shipman R, Schraml P, Moch H, Colombi M, Sauter G, Mihatsch M and Ludwig C (1997) p53 protein accumulation and p53 gene alterations (RFLP, VNTR and p53 gene mutations) in non-invasive versus invasive human transitional bladder cancer. International Journal of Oncology 10: 801–806
Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR and Frost P, et al (1991) Identification of p53 gene mutations in bladder cancers and urine samples. Science 252: 706–709
Spruck CHd, Rideout WMd, Olumi AF, Ohneseit PF, Yang AS, Tsai YC, Nichols PW, Horn T, Hermann GG, Steven K, Ross RK, Yu MC and Jones PA (1993) Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage [published erratum appears in Cancer Res 1993 May 15;53 (10 Suppl): 2427]. Cancer Res 53: 1162–1166
Steineck G, Wiholm BE and Gerhardsson de Verdier M (1995) Acetaminophen, some other drugs, some diseases and the risk of transitional cell carcinoma. A population-based case-control study. Acta Oncol 34: 741–748
Wada T, Louhelainen J, Hemminki K, Adolfsson J, Wijkstrom H, Norming U, Borgstrom E, Hansson J, Sandstedt B and Steineck G (2000) Bladder cancer: allelic deletions at and around the retinoblastoma tumor suppressor gene in relation to stage and grade. Clin Cancer Res 6: 610–615
Wales MM, Biel MA, el Deiry W, Nelkin BD, Issa JP, Cavenee WK, Kuerbitz SJ and Baylin SB (1995) p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med 1: 570–577
Varley JM, Evans DG and Birch JM (1997) Li-Fraumeni syndrome-a molecular and clinical review. Br J Cancer 76: 1–14
Warren W, Biggs PJ, el-Baz M, Ghoneim MA, Stratton MR and Venitt S (1995) Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours. Carcinogenesis 16: 1181–1189
Williamson MP, Elder PA and Knowles MA (1994) The spectrum of TP53 mutations in bladder carcinoma. Genes Chromosomes Cancer 9: 108–118
Xu X, Stower MJ, Reid IN, Garner RC and Burns PA (1997) A hot spot for p53 mutation in transitional cell carcinoma of the bladder: clues to the etiology of bladder cancer. Cancer Epidemiol Biomarkers Prev 6: 611–616
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Berggren, P., Steineck, G., Adolfsson, J. et al. p53 mutations in urinary bladder cancer. Br J Cancer 84, 1505–1511 (2001). https://doi.org/10.1054/bjoc.2001.1823
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1823
Keywords
This article is cited by
-
Competition between p53 and YY1 determines PHGDH expression and malignancy in bladder cancer
Cellular Oncology (2023)
-
The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells
BMC Cancer (2017)
-
Bladder cancer
Nature Reviews Disease Primers (2017)
-
MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1
BMC Urology (2013)
-
P53 mutations in urinary bladder cancer patients from Central Poland
Journal of Applied Genetics (2007)